Cullinan Therapeutics, Inc. CGEM Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cullinan Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cullinan Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities?
- Cullinan Therapeutics, Inc. (CGEM) reported unrealized gains (losses) on available-for-sale securities of -$893K in Q1 2026.
- How has Cullinan Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Cullinan Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities decreased by 240.0% year-over-year, from $638K to -$893K.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities?
- Over 3 years (2021 to 2025), Cullinan Therapeutics, Inc.'s unrealized gains (losses) on available-for-sale securities has grown at a 11.3% compound annual growth rate (CAGR), from -$836K to $1.15M.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric represents the change in the fair value of debt or equity securities classified as available-for-sale that has not yet been realized through a sale. It captures unrealized gains or losses that are excluded from net income and instead reported within other comprehensive income. Monitoring this figure helps investors understand the impact of market price fluctuations on the company's investment portfolio.